Gut bacteria products may boost harmful immune cells in MS

Credibility

Interest

Share:2 min read

Key Takeaway

Some gut bacteria make vitamin B products that can over-activate a special immune cell (MAIT) and may worsen inflammation in people with MS.

What They Found

Researchers grew MAIT cells from people with relapsing-remitting MS and from healthy people and tested how they reacted to small molecules made by gut bacteria that use vitamin B2 (riboflavin) or B9 (folate) pathways. MS patient MAIT cells reacted much more strongly when exposed to bacteria from the same patients, making more inflammatory signals like IFN-γ, IL-17, and GM-CSF and becoming better at killing target cells; these are immune actions that can increase inflammation. The way these MAIT cells reacted did not always match what mouse studies or simple DNA predictions expected, showing humans handle these bacterial vitamin products differently. For MAIT cells to be turned on, intact bacteria had to be taken up by cells and the bacterial molecules had to be loaded onto MR1 in an acid-dependent step (MR1 is the molecule that shows bacterial bits to MAIT cells). People with MS also showed signs of a leaky gut lining, which could let more bacterial products into the body and help explain why MAIT cells become over-active.

Who Should Care and Why

People with MS and their caregivers should care because the study suggests gut bacteria and the tiny chemical products they make can nudge immune cells toward more inflammation, which might affect symptoms or flare-ups. Think of the gut lining like a fence: if the fence is broken, more bacterial messages get through and can stir up immune cells inside the body. This matters for daily life because it points to possible ways to reduce inflammation, such as treatments that target gut bacteria, strengthen the gut lining, or block MAIT cell activation. Clinicians and researchers may use this information to design therapies that focus on the gut–immune connection rather than only treating the brain. Caregivers can consider talking with healthcare teams about gut health, diet, or trials that look at microbiome or barrier-targeted approaches as part of a broader MS plan.

Important Considerations

This study used cells taken from people and tested them in the lab, so results may not exactly match what happens inside the body. The findings are specific to relapsing-remitting MS and the particular bacteria studied, so they may not apply to every person with MS or to all gut bacteria. More research is needed to see if changing gut bacteria or repairing the gut lining will safely reduce MAIT cell activity and improve MS symptoms in real patients.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research Nutrition Immune-related Specific Symptoms

Article Topics:

MAIT cellscytokinescytotoxicityintestinal permeabilitymicrobiomemultiple sclerosis

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Multiple sclerosis (Houndmills, Basingstoke, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News